ANTIBIOTICS

Abstract: «Pseudomonic Acid D» of formula is metalbolite of Pseudomonas fluorescens and has antibacterial and antimycoplasmal activity.

Description: ANTIBIOTICS The present invention relates to novel antibiotics having activity against bacteria and mycoplasma. U.K. Patent No. 1,395,907 describes novel antibiotics produced by, and isolated from cultures of Pseudomonas fluorescens (NCIB 10586). Two of these, now known as "pseudomonic acid A" and "pseudomonic acid B" have the structure (I): EMI1.1 (I) : R=H, pseudomonic acid A R=OH, pseudomonic acid B European Patent Application No. 0 003 069 describes a further antibiotic produced by P. fluorescens, known as "pseudomonic acid C", having a structure (IA): EMI2.1 (IA) : pseudomonic acid C U.K. Patent No. 1,587,059 describes a related compound, "monic acid A", of structure (II): EMI2.2 (II) : R=H, monic acid A This patent also describes esters of monic acid A (ie, compounds of structure (II) wherein R is an esterforming radical), including esters wherein R is a C28 alkenyl group optionally substituted, inter alia with a carboxy group, which have antibacterial activity. It has now been found that a compound falling within the generic description of such esters, but not specifically disclosed in U.K. 1,587,059 has particular advantages not shared by the other compounds wherein R is a C28 alkenyl group. Accordingly, the present invention, in one aspect, provides the compound of formula (III): EMI3.1 and salts and esters of the terminal carboxyl group thereof. The compound of formula (III) has been named "pseudomonic acid D". It is known that the compound has the absolute stereochemistry shown in formula (III) above. Salts and esters of pseudomonic acid D may be pharmaceutically acceptable but this is not essential. Non-pharmaceutically acceptable salts and esters may be useful in separation and purification of pseudomonic acid D. Pharmaceutically acceptable salts include metal salts, (eg aluminium, alkali metal salts such as sodium or potassium, and alkaline earth metal salts such as calcium or magnesium) and ammonium or substituted ammonium salts (eg those with lower alkylamines such as triethylamine, hydroxy-lower alkylamines such as 2 hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylamine, N,N-dibenzylethylene-diamine, 1-ephenamine, N-ethylpiperidine, N-benzyl-ss-phenethyl-amine, dehydroabietylamine, N,N'-bis-dehydroabietylethylene-diamine, or bases of the pyridine type such as pyridine,.collidine or quinoline). Preferred salts are alkali metal salts. Suitable esters are C16 alkyl esters. The preferred ester is the methyl ester. Pseudomonic acid D is particularly advantageous in that it is produced by, and may be isolated from cultures of P. fluorescens (NCIB 10586). The other compounds disclosed in U.K. 1,587,059 are, of course, all semi-synthetic antibiotics. Accordingly, in a second aspect of the present invention provides the compound of formula (III) and salts and esters thereof as hereinbefore defined, substantially free from pseudomonic acids A, B and C. In a further aspect the present invention provides pseudomonic acid D, its salts and esters in substantially pure form. Preferably the acid, salt or ester is at least 50% pure, more preferably at least 75% pure, and most preferably at least 90% pure. Pseudomonic acid D, its salts and esters are preferably in crystalline form. Pseudomonic acid D may be produced by conve,lti.o.nal methods such as close descrilsed in U.K. Patent No. 1,587,059. Conveniently pseudomonic acid D may be produced by reacting a compound of formula (IV): EMI5.1 wherein X is a good leaving group, preferably a halogen atom or an alkyl or aryl sulphonate, and R is a carboxyl protecting group preferably trimethylsilyl, t-butylmethylsilyl or dimethylphenylsilyl, methyl or ethyl, with a salt of monic acid A (II: R=H), preferably the sodium salt. Most preferably X is chlorine, bromine or mesylate. The reaction is suitably carried out in an organic solvent, such as dimethylformamide, at 200 to 100 C. The carboxyl protecting group may be removed by standard methods, such as treatment with acid to remove trimethylsilyl, methyl or ethyl groups, and treatment with fluoride ions to remove t-butyldimethylsilyl and dimethylphenylsilyl groups. The product may be purified conventionally, for instance, chromatographically on silica. The compound of formula (IV) may be produced by conventional techniques, for instance, by the method outlined In Scheme I. EMI6.1 Scheme I Salts nd esters of pseudomonic acid D may be prodl.lced by conventional ntThods. Pseudomonic acid D may be obtained from its esters by hydrolysis either chemically or enzymatically, for instance, by using bakers yeast. Pseudomonic acid D may also be produced by fermentation of P. fluorescens (NCIB 10586). Fermentation is conducted conventionally, for instance as shown below in the Examples. The culture medium is then acidified and the pseudomonic acids extracted by repeated solvent extractions. The crude pseudomonic acids are then separated by hplc to afford pseudomonic acid D. The details of the process are given in the Examples below. As well as being useful as an antibiotic in its own right, pseudomonic acid D is useful as an intermediate in producing other antibiotics. Thus conventional hydrogenation of pseudomonic acid D affords pseudomonic acid A (I, R=H) and monic acid A may be obtained by hydrolysis of pseudomonic acid D, for instance by the methods described in U.K. Patent No. 1,587,058. Accordingly, the present invention provides a process for producing pseudomonic acid A, which process comprises hydrogenating pseudomonic acid D. The present invention also provides a process for producing monic acid A, which process comprises hydrolysing pseudomonic acid D. Pseudomonic acid D is an active antibiotic and may be used in human and veterinary treatment. Accodin1y, the prevent invention provides a pharmaceutical cos osition comprising pseudomonic acid D or a pharr.laceutically acceptable salt or ester thereof in association with a pharmaceutically acceptable carrier therefor. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. Suppositories will contain conventional suppository bases, e.g. cocoa-butters or other glyceride. or parente ral administration, fluid unit dosage foms rJre prepared utilizincj the comrJound and a sterile vehicle. The compound, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability the composition can be frozen after filling into the vial and water removed under vacuum. The dry lypophilized powder is then sealed in the vial. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compounds. The compositions may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of adminstration. Where the compositions comprises dosage units, each unit will preferably contain from 50-500 mg, of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 mg to 3 g, per day, for instance 250 mg to 2 g per day, depending on the route and frequency of administration. Alternatively pseudomonic acid D or a pharmaceutically acceptable salt or ester may be administered as part of the total dietary intake. In this case the amount of compound employed may be less than 1% by weight of the diet and it preferably to ore than 0.5%by weight. The diet for animals may consist of normal feedstuffs to which the confound z.ay be added or it may be aided to a premix. A suitable method for administering pseudomonic acid D or a pharmaceutically acceptable salt or ester thereof to animals is to include it in the drinking water provided for the animals. In this case the concentration of the compound in the drinking water would be from about 5 to 500 pg/ml, for example 5 to 200 pg/ml. The present invention also provides a process for producing a composition as defined above, which process comprises bringing into association pseudomonic acid D or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier therefor. The present invention further provides a method for treating humans or other animals which method comprises administering an effective non-toxic amount of pseudomonic acid D, or a pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition thereof, to a human or other animal suffering from a bacterial or mycoplasma infection. Typically, pseudomonic acid D or a pharmaceutically acceptable salt or ester thereof would be administered at 1 mg/kg body weight per day to 50 mg/kg, especially 2.5 mg/kg to 25 mg/kg when given internally. The invention will now be illustrated with references to the following Examples, which are not intended to limit the invention in any way. e LE 1 Production of Pseudomonic Acid D by Fermentation Pseudomonas fluorescens, strain NCIB 10586 was cultured on an ayar slope and flooded with sterile water. A sample was added to the following seed stage medium: Oxoid yeast extract: 2 (%w/v) Glucose: 0.11 Disodium hydrogen orthophosphate: 0.26 Potassium dihydrogen orthophosphate: 0.24 This was incubated at 280C overnight and then used to inoculate the following production stage medium: Corn steep liquor: 0.3 (%w/v) Glucose: 2.0 Glycerol: 0.5 Ammonium sulphate: 0.2 Calcium carbonate: 0.4 Potassium dihydrogen orthophosphate: 0.04 Disodium hydrogen orthophosphate: 0.065 Manganese chloride 4 H2O: 0.0003 Potassium chloride: 0.05 Magnesium sulphate 7 H2O: 0.0375 P2000 to minimise foaming The fermentation was carried out at 250C for 48 hours. (b) Isolation of Pseudomonic Acid D from Culture Medium Culture medium (1500 1) was partially clarified on a rotary pre-coat filter and further clarified by centrifugation giving clarified liquor (1285 1). This was acidified to pH 4.5 using hydrochloric acid (5()%) and was extracted with .ethyl isobutyl ketone (IBK; 300 1) by metering the liquor at 8 1 min-1 and solvent at 2 1 min-l into an in-line static mixer. The two phases were separated by centrifugation and the organic extract was extracted with sodium bicarbonate solution (28 w/v, 60 1) pre-adjusted topH 3.5. The phases were separated by centrifugation. MIBK (12 1) was added to the aqueous extract and the aqueous phase was acidified to pH 4.5 using hydrochloric acid (50%). The organic phase was separated, washed with deionised water (6 1), and then concentrated to 1.5 1. The concentrate was dried with magnesium sulphate. The magnesium sulphate was removed by filtration and n-heptane (760 ml) added to the dry solution. The mixture so produced was left to stand at 50C for 12 hours. The product was filtered and washed with MIBK/heptane (50:50; 1 1) and then with heptane (1 1) and dried in vacuo at 250C. This material (125 g) was shown by hplc analysis to contain 92-93% of pseudomonic acid A and # 2% of pseudomonic acid D. The crude product so produced was dissolved in dry tetrahydrofuran (THF; 1.5 ml) and chromatographed in portions (200-250 pl) by high performance liquid chromography (hplc) using an Altex ultrasphere-octyl (250 mm x 10 mm) reverse phase column and eluting at a flow rate of 3 ml/min of ammonium acetate buffer (0.1M; pH 5.7): TllF (3:1). Pseudomonic acid D had a retention time of 30 minutes (pseudomonic acid A Rt = 41 mins). The combined eluents containing the pseudomonic acid D peaks (detected by UV at max 240 nm) were evaporated to dryness, then the residue dissolved in water and adjusted to pH 4 using hydrochloric acid (lM)r under a layer of ethyl acetate (20 ml). The organic phase was separated and the aqueous phase further extracted with ethyl acetate (3 x 20 ml), then the combined extracts shed with Urine, dried with magnesium sulphate and evaporated to dryness. The pseudomonic acid D obtained was rechromatographed by hplc as above and the combined eluents evaporated to remove the THF, then the aqueous solution was adjusted to pH 7 and washed with ethyl acetate. The aqueous layer was acidified to pH 4 using hydrochloric acid (1M) under a layer of ethyl acetate (25 ml) and the aqueous layer further extracted with ethyl acetate (3 x 25 ml). The combined extracts were dried using magnesium sulphate and evaporated to yield pseudomonic acid D (30 mg). i.r. spectrum # max (CHCl3) 3400, 1720 and 1650 cm-1; U.V. spectrum 4max (EtOH) 225 nm; 1H nmr #H (CDCl3) 5.76 (1H, m, H-2), 5.45 (2H, m, CH=CH, J=15Hz), 4.08 (3H, t, CH2-9'), 3.91 (1H, dd, H-7), 3.87 and 3.54 (2H, m, CH2-16), 3.80 (1H, m, H-13), 3.76 (1H, m, H-5), 3.47 (1H, dd, H-6), 2.83 (1H, dt, H-10), 2.73 (1H, dd, H-ll), 2.59 and 2.30 (2H, m, CH2-4), 2.40 (2H, t, CH2-2'), 2.32 (2H, m, CH2-3'), 2.21 (3H, d, CH3-15), 2.02 (2H, 'm, CH2-6'), 2.00 (1H, m, H-8), 1.73 (2H, m, CH2-9), 1.63 (2H, m, CH2-8'), 1.44 (2H, m, CH2-7'), 1.38 (1H, m, H-12), 1.22 (3H, d, CH3-14), 0.94 (3H, d, CH3-17). 13C nmr & (CDC13) 178.0 (C1'), 166.9 (C1), 156.6 (C3), 131.4 (C5'), 128.5 (C4'), 117.8 (C2), 75.2 (C5), 71.4 (C13), 70.6 (C7), 69.2 (C6), 65.5 (C16), 63.8 (C9'), 61.3 (Cll), 55.7 (C10), 42.9 (C4, 12), 39.6 (C8), 34.2 (C2'), 32.0, 31.8, 28.1, 27.8, 25.9 (C6', 9, 8', 7', 3'), 20.8 (C17), 19.3 (C15), 12.7 (C17). Mass spectrum m/e (relative intensity) 498 (M+, 3) 396 (4), 327 (10), 309 (16), 291 (5), 254 (23), 27 92), 209 (30), 141 (49), 137 (39), 129 (22), 111 (100) (Found: 498.2860. C26H42Og requires 498.2892) ( Found: 254.1505. C14H2204 requires 254.1944). Structure Elucidation of Pseudomonic Acid D isolated from NCIB 10586 EMI14.1 Purified pseudomonic acid D was shown by high resolution mass spectroscopy to have a molecular weight of 498.2860 indicating a molecular formula of C26H42O91 which is two hydrogen atoms less than that of pseudomonic acid A. The infra red spectrum had absoptions at # max 1720 (C=O) and 1650 (C=C) cml indicating the compound to be an unsaturated ester, which was confirmed by the u.v. absoption at # max 225 nm, thus showing the structural similarity of pseudomonic acid D to the other three naturally occurring metabolites, pseudomonic acids A, B and C. The 13C and 1H nmr spectra of pseudomonic acids A and D also indicated structural similarities. The 13C nmr spectrum of pseudomonic acid D contained all of the resonances associated with the epoxide-containing nucleus of pseudomonic acid A, ie carbons 1-17. However, in addition to the usual low d Carbon resonance of C1, C2, C3 and C1', two further resonances at at # C 131.4 and 128.4, which appeared as doublets in the off resonance spectrum, indicated the presence of a disubstituted carbhon, crbon double bond in a nine carbon ester side chain. The presence of six methylene triplets in the off resonance spectrum also confirmed the absence of branching in the nonenoic acid side chain. The location of the double bond and the assignment of it geometry were determined by high resolution 250 MHz 1Hnmr spectroscopy. The most notable feature of the 1H nmr spectrum is comparison with that of pseudomonic acid A was the presence of signals due to two olefinic protons appearing as a complex multiplet centred at 2 s.4s in deuteriochloroform. After addition of deuteriated water to exchange the hydroxyl protons and thus sharpen the spectrum, a series of spin-spin decoupling experiments were carried out. The initial studies confirmed the integrity of the C1-17 nucleus with assignments of the respective proton signals. The remaining protons unassigned were those of the nonenoic acid side chain and consisted of a multiplet at # 5.45 for the two olefinic protons, a two proton triplet at 4.08 and five two-proton multiplets at # 2.40 2.32, 2.02, 1.63 and 1.44. The triplet at g4.08 was assigned to the CH2-9' adjacent to the acrylic ester function. Further assignments are based on the following experimental observations: C (a) Irradiation of the triplet 44.08 produced a considerable simplification of the multiplet at 21.63. This signal then showed 2nd order coupling and was perturbed to high field. Irraditation at # 1.63 collapsed this triplet to a broad sintlet. (b) Irradiation of the olefinic multiplet at 95.45 produced simplication of the multiplets at t 2.32 and 2.02. The resonance at # 2.32 then had 2nd order characteristics and was very strongly perturbed to low field, whilst that at # 2.02 became a discernable triplet even though H-8 was superimposed. (c) Irradiation at # 2.02 simplified the low field half of the olefinic region and collapsed the multiplet at t1.44 to 2nd order appearance perturbed to low field. (d) Irradiation at i2.32 simplified the hiqh field half of the olefinic region but had no effect on any of the observable methylenes. The resonance at 22.40 was too close to observe. The resonance at 22.40 had 2nd order characteristics and was perturbed very strongly to high field. Irradiation at # 2.40 had no effect on the observable methylenes. Perturbation and appearance implied that these two methylene signals are coupled to each other. A chemical shift of i2.40 is in close agreement with that of the CH2 adjacent to the acid carboxyl in pseudomonic acid A. The evidence of chemical shift and response to irradiations, as well as the implications arrived at from perturbations and 2nd order characteristics lead to the proposed construction of the side chain shown below: 9' 8' 7' 6' 5' 4' 3' 2' 1' - QO - CH2 - CH2 - CH2 - CH2 - CH - CH - CH2 - CH2 - CC 0 4.08 1.63 1.44 2.02 5.48 5.42 2.32 2.40 Confirmation of the structure of the side chain was provided by using the Inter Nuclear Double Resonance (INDOR) technique. The method clearly established the connectivity of four methylenes at C6'-9', when initially observing the resonance at 94.08 assigned to CH2-9'. The double resonance experiments showed clearly that the resonance at 2.02 assigned to the CH2-6' was coupled to the low field olefinic proton at 5,48. Thus the double bon is located between C4' and C5'. The stereochemistry of the double bond was confirmed as trans from the coupling constant J4',5' = 15 + 0.2 Hz, which was measured after iradiation of CH2-3' at i2.32 and also CH2-6' at S2.02. The assignment of the trans geometry was confirmed by computer simulation using the Brucker PANIC 9081 computer programme, (Parameter Adjustment in NMR by Interaction Calculation). When programmed with the chemical shifts, coupling constants, linewidths etc., measured from the spectrum, the computer simulated an almost identical spectral pattern to that which is obtained experimentally. Using the same parameters but with a coupling constant J = 9.11 Hz (appropriate for a cis geometry), the simulated spin-system was not comparable with that observed experimentally. The structure of pseudomonic acid D is, therefore, confirmed with trans 4' double bond present in the ester side chain. L Pi.E 2 Synthesis of Pseudomonic Acid D from bionic Acid A (a) 9-Hydroxynon-4z-enoic acid Butyl lithium (1.18M in toluene, 17 ml) was added to a solution of (3-carboxypropyl)triphenylphosphonium chloride (3.84 g) in dimethylsulphoxide (20 ml) at OOC. The resulting deep red solution was diluted with tetrahydrofuran (20 ml) and stirred for 2 h then treated with 2-hydroxytetrahydropyran (1.1 g). The mixture was stirred overnight at room temperature then poured into water and acidified and extracted with ether. The combined organic layers were extracted with lM-sodium hydroxide which was finally acidified and extracted with ether. After drying (magnesium sulphate) the extract was evaporated to an oil which was chromatographed on silica (10 g) eluting with 2 to 6% methanol in dichloromethane to yield 9-hydroxynon4Z-enoic acid as an oil (0.225 g, 13%), g.l.c. indicated the product to contain 92% of the eis-isomer and 8% of the trans: i.r. spectrum Vmax (film) 2300-3700 (broad), 1715 (broad) cm-1; 1H nmr SH (CDCl3) 1.43 (2H, m, CH2-7), 1.57 (2H, m, CH2-8), 2.09 (2H, q, CH2-6), 2.38 (4H, m, CH2-2 and CH2-3), 3.64 (2H, t, CH2-9), 5.40 (2H, m, J=llHz, CH-4 and CH-5); 13C nmr SC (CDCl3) 176.7 (Cl), 131.1 (C5), 127.8 (C4), 62.4 (C9), 34.2 (C2), 32.1 (C8), 26.9 (C7), 25.7 (C6), 22.8 (C3). (b) Methyl 9-chloronon-4E-enoate A solution of 9-hydroxynon-4Z-enoic acid (0.5 g) and diphenyldisulphide (0.634 g) in benzene (150 ml) was photolysed (6 W low pressure mercury lamp) for 42 under argon. The solution was evaporated to an oil which was rcdissolved in ether and extracted with 1M- sodium hydroxide. After acidification, the aqueous phase was re-extracted with ether and the extracts dried (magnesium sulphate) then evaporated to an 0:1, which was dissolved in benzene (20 ml), thionyl chloride (2 ml) was added and the solution heated unde. reflux for 4 h. After evaporation of the solvent and excess reagent, the residual oil was dissolved in methanol and stirred overnight at room temperature. The solution was evaporated under reduced pressure, t oil dissolved in ether and washed with aqueous sodium bicarbonate, brine and dried (magnesium sulphate), the: evaporated to yield methyl 9-chloronon-4E-enoate as an oil (0.415 g, 70%), g.l.c. indicated the product to contain 86% of the trans-isomer and 14% of the cis; i.r. spectrum Vmax (film) 1738 cm-l; 1H nmr SH (CDCl3) 1.49 (2H, m, CH2-7), 1.63 (2H, m, CH2-8), 1.98 (2H, m, CH2-6), 2.32 (4H, m, CH2-2 and CH2-3), .48 (2, t, CH2-9), 3.62 (3H, s, OCH3), 5.42 (2H, m, CH-4 and CH-5). (c) Methyl pseudomonate D Methyl 9-chloro-non-4E-enoate (0.415 g), sodium odlie (0.3 g) and sodium monate A (0.817 g) in N,N-dimethyl- tormamide (25 ml) were heated at bu C for 18 h. The solvent was removed under reduced pressure and the residue extracted with ether-briac. The organic, was washed with aqueous sodium bicarbonate, brine and dried (magnesium sulphate) then evaporated under reduced pressure. The residual oil was chroato:jraphed on silica (6 g) eluting with 0 to 4% methanol in dichloromethane and fractions containing product (t.l.c.) were combined and evaporated to yield methyl pseudomonate D as a oil (0.333 g, 32%): i.r spectrum #max (CHCl3) 3430 (broad), 1722, 1708 and 1645 cm-1; U.V. spectrum human (EtOH) 219 nm (#m18,579); 1H nmr and 13C nmr both the #H and #C indicated that the product consisted of 80% trans and 20% cis of the C4', 5' double bond. Major isomer: lH nmr #H (CDCl3) 0.95 (3H, d, CH3-17), 1.22 (3H, d, CH3-14), 1.42 (2H, m, CH2-7'), 1.63 (2H, m, CH2-8'), 2.01 (2H, m, CH2-6'), 2.21 (3H, d, CH3-15), 2.32 (4H, m, CH2-2'; CH2-3'), 3.67 (3H, s, OCH3), 4.07 (2H, t, CH2-9'), 5.43 (2H, m, J=14Hz, CH-4'; CH-5'), 5.75 (1H, broad, H-2); 13C nmr C C CDCl3) 173.8 (C1'), 166.9 (Cl), 156.9 (C3), 131.2 (C5'), 128.5 (C4'), 117.5 (C2), 75.0 (C5), 71.0 (C13), 70.3 (C7), 69.0 (C6), 65.4 (C16), 63.6 (C9'), 61.2 (Cll), 55.6 (C10), 51.5 (OCH3), 42.9 (C12), 42.8 (C4), 39.6 (C8), 34.1 (C2'), 32.0 (C6'), 31.7 (C9'), 28.1 (C8'), 27.9 (C3'), 25.8 (C7'), 20.7 (C14), 19.1 (C15), 12.6 (C17); @ars spectrum m/e (relative intensity) 512 (M+, 1%), 410 (1), 364 (2), 327 (6), 309 (8), 268 (10), 227 (37), 111 (72), 9' (73) (Found: 512.3026. C27H44O9 requires 512.3070). EXAMPLE 3 Sodium pseudomonate D Methyl pseudomonate D (0.136 g) was dissolved in N,N-dimethylformamide (4.5 ml) and diluted with phosphate buffer (0.05M, pH 7, 60 ml). Bakers yeast (5 g) was added and the mixture stirred vigorously for 18h at room temperature. The yeast was removed by centrifugation and the aqueous layer acidified to pH 4 then extracted with ethyl acetate (4 x 25 ml). The combined extracts were dried (magnesium sulphate), evaporated to an oil (0.076 g) which was dissolved in methanol (1 ml) and treated with sodium bicarbonate (0.013 g) in water (1 ml). Evaporation to dryness gave sodium pseudomonate D (0.076 g, 50%): i.r spectrum pmax (nujol) 3400 (broad), 1710, 1647 and 1558 (broad) cm-1; U.V. spectrum #max (EtOH) 223 nm (#m 14,404); 1H nmr and 13C nmr gH and SC indicated that the product consisted of > =80% trans ( < =20% cis) of the C4',5' double bond. Major isomer: 1H nmr #H (CD30D) 0.95 (3H, d, CH3-17), 1.20 (3H, d, CH3-14), 1.42 (2H, m, CH2-7'), 1.65 (2H, m, CH28')r 2.01 (2H, m, CH2-6'), 2.18 (3H, d, CH3-15), 2.23 (4H. m, CH2-2'; CH2-3'), 4.06 (2H, t, CH2-9'), 5.46 (2H, @ CH-4'; CH-5'), 5.74 (lH, s, H-2); 13C nmr #C (CD30D) 181.8 (Cl'), 168.4 (C1), 158.8 (C3), 131.5 (C5'), 130.9 (C4'), 118.3 (C2), 76.3 (C5), 71.6 (C13), 70.8 (C7), 70.0 (C6), 66.3 (C16), 64.7 (C9'), 61.5 (C11), 56.8 (C10), 43.9 (C12), 43.8 (C4), 41.5 (C8), 38.8 (C2'), 33.1, 33.0 (C6', 9), 30.5 (C7'), 2 (C8'), 27.0 (C3'), 20.5 (C14), 19.4 (C15), 12.3 (C17) Microanalysis (Found: C, 59.7; H, 7.8 C26H41 9Na requires C, 60.0; H, 7.9%. Biological Data a) Mycoplasma The activity of the compounds of the Examples against various mycoplasmal organisms was assayed in vitro in Friis broth solidified with 0.9% agarose and inoculated with 103 to 105 C.F.U. The minimum inhibitory concentrations (MIC's) were determined after incubation for 6 days at 370C and are shown in Table I. b) Veterinary Bacteria The activity of the compounds of the Examples against various veterinarily important bacteria, was assayed in vitro using two-fold serial dilutions in Diagnostic Sensitivity Test Agar inoculated with 104 organisms. The MIC's-were determined after incubation for 18 hours at 370C and are shown in Table 2. c) Human Bacteria The activity of the compounds of the Examples against various bacteria which are important in diseases of humans, was assayed in vitro using serial dilutions in nurient agar with 5% chocolated horse blood. The MIC's were determined after incubation for 18 hours at 370C and are shown in Table 3. Table 1 MIC's (ly/ml) against Mycoplasma EMI25.1 <tb> <SEP> Organism <SEP> Compound <SEP> of <SEP> Exa <tb> <SEP> 1 <tb> <SEP> M. <SEP> suipneumoniae <SEP> NB12 <SEP> 1.0 <tb> <SEP> M. <SEP> suipneumoniae <SEP> JF <SEP> 435 <SEP> 5.0 <SEP> 5.0 <tb> <SEP> M. <SEP> suipneumoniae <SEP> HK(2) <SEP> 5.0 <SEP> 5.0 <tb> M. <SEP> suipneumoniae <SEP> Str. <SEP> 11 <SEP> 1.0 <SEP> 2.5 <tb> <SEP> M. <SEP> suipneumoniae <SEP> J2206/l83b <SEP> 2.5 <SEP> 5.0 <SEP> <tb> <SEP> M. <SEP> suipneumoniae <SEP> MS <SEP> 16 <SEP> 2.5 <SEP> 2.5 <tb> <SEP> M. <SEP> suipneumoniae <SEP> PW/C/210 <SEP> 1.0 <SEP> 2.5 <tb> <SEP> M. <SEP> suipneumoniae <SEP> LABER <SEP> 2.5 <SEP> 2.5 <tb> <SEP> M. <SEP> suipneumoniae <SEP> UCD <SEP> 1 <SEP> 5.0 <SEP> 5.0 <tb> <SEP> M. <SEP> suipneumoniae <SEP> TAM <SEP> 6N <SEP> 5.0 <SEP> 10 <tb> <SEP> M. <SEP> suipneumoniae <SEP> ATCC <SEP> 25095 <SEP> 1.0 <SEP> 2.5 <tb> <SEP> M. <SEP> suipneumoniae <SEP> NCTC <SEP> 10110 <SEP> 5.0 <SEP> 5.0 <tb> <SEP> M. <SEP> hyorhinis <SEP> ATCC <SEP> 23234 <SEP> 1.0 <SEP> 1.0 <tb> <SEP> M. <SEP> hyorhinis <SEP> ATCC <SEP> 25021 <SEP> 1.0 <SEP> 1.0 <tb> <SEP> M. <SEP> hyosynoviae <SEP> ATCC <SEP> 25591 <SEP> 0.5 <SEP> 0.5 <tb> M. <SEP> bovis <SEP> NCTC <SEP> 10131 <SEP> 0.05 <SEP> 0.05 <tb> <SEP> M. <SEP> bovigenitalium <SEP> ATCC <SEP> 14173 <SEP> 0.1 <SEP> 0.1 <tb> <SEP> M. <SEP> dispar <SEP> NCTC <SEP> 10125 <SEP> 2.5 <SEP> 1.0 <tb> <SEP> M. <SEP> gallisepticum <SEP> S6 <SEP> > 10 <SEP> > 10 <tb> <SEP> M. <SEP> pneumoniae <SEP> ATCC <SEP> 15492 <SEP> NG <SEP> <SEP> > 10 <SEP> <tb> NG - Organism failed to grow in test NT - Not tested Table 2 MIC's ( g/ml) against Veterinary Bacteria EMI26.1 <tb> <SEP> Compound <SEP> of <SEP> Example <SEP> No. <tb> <SEP> Organism <tb> <SEP> 1 <SEP> 2 <tb> E. <SEP> coli <SEP> NCTC <SEP> 10418 <SEP> A <SEP> <SEP> 20 <SEP> 40 <tb> E. <SEP> coli <SEP> El <SEP> > 20 <SEP> 40 <tb> S. <SEP> dublin <SEP> S7 <SEP> > <SEP> 20 <SEP> 80 <tb> S. <SEP> typhimurium <SEP> S18 <SEP> C > 20 <SEP> 80 <tb> Bord. <SEP> bronchiseptica <SEP> BOS <SEP> 10 <SEP> 40 <tb> Bord. <SEP> bronchiseptica <SEP> B09 <SEP> 5 <SEP> 10 <tb> Past. <SEP> multocida <SEP> PA1 <SEP> 0.156 <SEP> 10 <tb> Past. <SEP> multocida <SEP> PA2 <SEP> ( <SEP> 0.019 <SEP> 2.5 <tb> Past. <SEP> haemolytica <SEP> PA5 <SEP> 2.5 <SEP> 1.25 <tb> Erysipelothrix <SEP> rhusiopathiae <tb> <SEP> NCTC <SEP> 8163 <SEP> 10 <SEP> 20 <tb> Corynebacterium <SEP> pyogenes <SEP> CYl <SEP> NT <SEP> 80 <SEP> <tb> Staph. <SEP> aureus <SEP> B4 <SEP> (pen. <tb> <SEP> resistant) <SEP> 0.312 <SEP> 80 <tb> Staph. <SEP> aureus <SEP> 152 <SEP> (pen. <tb> <SEP> sens) <SEP> 0.312 <SEP> 0.625 <tb> Staph. <SEP> aureus <SEP> Oxford <SEP> 0.312 <SEP> 0.625 <tb> Strep. <SEP> suis <SEP> (qroup <SEP> D) <SEP> SPS11 <SEP> 1.25 <SEP> 0.625 <tb> Strep. <SEP> uberis <SEP> SPU1 <SEP> 0.039 <SEP> 5.0 <tb> Strep. <SEP> dysgalactiae <SEP> SPD1 <SEP> 0.156 <SEP> 0.156 <tb> Strep. <SEP> agalactiae <SEP> SPA1 <SEP> 0.625 <SEP> 0.312 <tb> B. <SEP> subtilis <SEP> ATCC <SEP> 6633 <SEP> NG <SEP> NT <tb> NG - organism failed to grow in test NT - not tested Table 3 MIC's ( g/ml) aqainst Human Bacteria EMI27.1 <tb> <SEP> Compound <SEP> of <SEP> Example <SEP> No <tb> <SEP> Organism <tb> <SEP> 2 <SEP> <tb> E. <SEP> coli <SEP> NCTC <SEP> 10418 <SEP> <SEP> 25 <SEP> 25 <SEP> > <SEP> 100 <tb> E. <SEP> coli <SEP> ESS <SEP> 1.0 <SEP> 1.0 <tb> P. <SEP> mirabilis <SEP> 889 <SEP> > <SEP> 25 <SEP> - <SEP> <SEP> 100 <tb> K. <SEP> aerogenes <SEP> A <SEP> > <SEP> 25 <SEP> > <SEP> 100 <tb> Ps. <SEP> aeruginosa <SEP> NCTC <SEP> 10662 <SEP> > <SEP> 25 <SEP> ? <SEP> 100 <tb> Pasteurella <SEP> multocida <SEP> 1633 <SEP> 0.25 <SEP> 0.5 <tb> Haemophilus <SEP> influenzae <SEP> Q1 <SEP> 0.25 <SEP> 0.5 <tb> Haemophilus <SEP> influenzae <SEP> Wy21 <SEP> - <SEP> 0.1 <tb> Neisseria <SEP> catarrhalis <SEP> 1502 <SEP> 0.5 <SEP> 0.5 <tb> Bacillus <SEP> subtilis <SEP> 6633 <SEP> 1.0 <SEP> 0.5 <tb> Corynebacterium <SEP> xerosis <SEP> 9755 <SEP> > <SEP> 25 <SEP> > <SEP> 100 <tb> Sarcina <SEP> lutea <SEP> 8340 <SEP> > <SEP> 25 <SEP> > <SEP> 100 <tb> Staph. <SEP> aureus <SEP> Oxford <SEP> 1.0 <SEP> 0.5 <tb> Staph. <SEP> aureus <SEP> Russell <SEP> 1.0 <SEP> 2.5 <tb> Staph. <SEP> aureus <SEP> W2827 <SEP> 1.0 <SEP> 1.0 <tb> Strep. <SEP> faecalis <SEP> I <SEP> > <SEP> 25 <SEP> ) <SEP> 100 <tb> Strep. <SEP> pyogenes <SEP> R80/421-A <SEP> 0.5 <SEP> NT <tb> Strep. <SEP> pyogenes <SEP> B2788 <SEP> 0.5 <SEP> 2.5 <tb> Strep. <SEP> pyogenes <SEP> 64/848-C <SEP> . <SEP> 0.25 <SEP> NT <tb> Strep. <SEP> pneumoniae <SEP> CN33 <SEP> 0.25 <SEP> 2.5 <tb> NT - not tested

Claims: CLAIMS 1. Pseudomonic Acid D and salts and esters of the terminal carboxyl group thereof. 2. Alkali metal salts of pseudomonic acid D as claimed in claim 1. 3. Sodium pseudomonate D. 4. C16 alkyl esters of pseudomonic acid D as claimed in claim 1. 5. Methyl pseudomonate D. 6. Pseudomonic acid D and salts and esters thereof as claimed in claim 1 and substantially free from pseudomonic acids A, B and C. 7. Pseudomonic acid D and salts and esters thereof as claimed in claim 1 or claim 6 in substantially pure form. 8. A process for producing pseudomonic acid D and salts and esters thereof as claimed in claim 1 which process comprises culturing organisms of Pseudomonas fluorescens (NC1B 10586) and recovering pseudomonic acid D or salts or esters thereof from the culture medium. 9. A process for producing pseudomonic acid D and salts and esters thereof as claimed in claim 1 which process comprises reacting a monic acid salt with a compound of formula (IV). EMI29.1 wherein X is a good leaving group. 10. A pharmaceutical composition comprising pseudomonic acid D or a salt or ester thereof in association with a pharmaceutically acceptable carrier therefore. 11. A process for producing pseudomonic acid A which process comprises hydrogenating pseudomonic acid D or a salt or ester thereof as defined in claim 1. 12. A process for producing monic acid A which process comprises hydrolysing pseudomonic acid D or a salt or ester thereof as defined in claim 1.

Inventors: O'HANLON, PETER JOHN
Applicants: BEECHAM GROUP PLC
Application year: 1982
Main classification: C07D407
IPC codes: A61P33, C07D407, C12R1, A61K31, A61P31, C12P17